ArticleInternational journal of clinical and experimental pathology2019
Anti-EGF antibody cationic polymeric liposomes for delivery of the p53 gene for ovarian carcinoma therapy.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Liposomal delivery of gene therapy for ovarian cancer: a systematic review.Reproductive biology and endocrinology : RB&E · 2023Pooled it
- Advancements inMolecules (Basel, Switzerland) · 2024Review
- Current Update on Nanotechnology-Based Approaches in Ovarian Cancer Therapy.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Delivery of cancer therapies by synthetic and bio-inspired nanovectors.Molecular cancer · 2021Review
- Gene Therapy in Cancer Treatment: Why Go Nano?Pharmaceutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cationic polymeric liposomes (CPLs) were successfully prepared using a tumor-targeting EGF protein modification for the systemic delivery of the p53 gene in ovarian cancer. These functional CPL nanoparticles (NPs) can be used as effective gene delivery vectors and are composed of an EGF derivative (EGF-GHDC), cholesterol, and DOPE, which have lower gene transfection efficiencies compared with Lipofectamine 2000. The increased therapeutic efficiency of p53 gene-loaded EGF-CPL was tested in SKOV3 cells and compared with p53 gene-loaded CPL and free p53 gene in solution. In addition, EGF-CPL (effective diameter: 95.01±4.05 nm; polydispersity index: 0.270) significantly enhanced luciferase gene expression in vivo 3 days post-injection of pGL-3/NPs complexes. In conclusion, EGF-targeted CPL has the potential for use as an effective drug delivery system.
Indexed as
Identifiers
31933735PMC6944014W3008192021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.